Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AdvaMed Pans CMS Plan To Mandate Publicizing Hospital Rates, But Likes Pay Path For Breakthrough Devices

Executive Summary

AdvaMed took issue with several aspects of a US Centers for Medicare and Medicaid Services (CMS) outpatient payment system draft rule mandating that hospitals publicize prices for their surgical procedures and laboratory tests, in comments on the draft. But the medtech industry advocacy group, as well as the Medical Device Manufacturers Association (MDMA), say they support another provision – the agency's new Medicare coverage and payment proposal for breakthrough devices – and requested only minor tweaks to the plan.

You may also be interested in...

Congress Tackles Overpriced ‘Surprise’ Medical Bills, Taking Several Different Tacks

A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.

US Insurers, Hospitals, Medtech Industry Say Transparency Rule Touted In President’s Speech Is Anticompetitive

US President Donald Trump in his State of the Union address on 4 February touted his 2019 Price Transparency executive order calling on federal agencies to require private hospitals and insurers to publicly reveal the costs of hundreds of their device-related procedures and lab tests – as well as insurers’ negotiated rates for them – so patients can shop for their own health care. But industry maintains the resulting rules out of the Centers for Medicare and Medicaid Services are “anticompetitive,” and a coalition of hospital groups is suing the Department of Health and Human Services to stop their implementation.

Device-Related Procedure Costs To Be Revealed Under CMS Proposed Payment Rule

US hospitals would have to reveal on a public website their standard charges and insurer-negotiated prices for a long list of device-related procedures, advanced imaging scans, and lab tests under a proposed Centers for Medicare and Medicaid Services rule released on 29 July.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts